pharma · Solid Tumor, Adult · Advanced Soft-tissue Sarcoma · MNPR
Monopar Therapeutics
Monopar Therapeutics is a pharma organization headquartered in Wilmette, USA. It trades on NYSE under ticker MNPR. Primary therapeutic focus areas include Solid Tumor, Adult, Advanced Soft-tissue Sarcoma, Chemoradiothera
Wilmette, USA HQ
2015 Founded
22 Employees
Public company Type
MNPR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Wilmette, USA
- Founded
- 2015
- Employees
- 22
- Programs
- 4
- Drugs
- 3
- Patents
- 3
Camsirubicin
Phase 1 · small molecule · Advanced Soft-tissue Sarcoma
Camsirubicin for Advanced Soft-tissue Sarcoma is a Phase 1 program (small_molecule) at Monopar Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code MNPR-201-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Monopar Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Advanced Soft-tissue Sarcoma
- Status
- terminated
- Trials
- 1